The Smokers We Treat vs. Those We Study

The profile of the smoking population in the developing world has changed dramatically in recent decades. The era when smoking was normative among adults is gone, to be replaced by one in which those people still smoking tend to be low income and/or have mental health and alcohol/drug problems.

You might think that this new world of smoking would led smoking cessation researchers to focus intensely on how to help smokers who have comorbid problems. But as my colleague Anna Lembke and I describe in the current issue of Tobacco Control, just the opposite is true:

One review of the smoking cessation trial literature found that 40% excluded depressed smokers, 55% excluded smokers with alcohol use disorders and 59% excluded those taking psychiatric medications. One critic described the practice of excluding smokers with mental health issues as ‘scandal’, which is reasonable given the stunning 62% rate of smoking among people with schizophrenia, the 42.6% rate of binge drinking among all smokers, and the enormous tobacco-related health damage in the seriously mentally ill population.

Smoking cessation research is one of too many cases where the science that is supposed to guide medical practice for all patients is generated primarily by studying relatively healthy, wealthy, happy and young research subjects. A scandal indeed.

[Cross-posted at The Reality-Based Community]

Washington Monthly - Donate today and your gift will be doubled!

Support Nonprofit Journalism

If you enjoyed this article, consider making a donation to help us produce more like it. The Washington Monthly was founded in 1969 to tell the stories of how government really works—and how to make it work better. Fifty years later, the need for incisive analysis and new, progressive policy ideas is clearer than ever. As a nonprofit, we rely on support from readers like you.

Yes, I’ll make a donation

Keith Humphreys

Keith Humphreys is a professor of psychiatry at Stanford University. He served as a senior policy advisor at the White House Office of National Drug Control Policy from 2009 to 2010.